Different Effects of Metabolic Syndrome on Dementia According to Dementia Type: Analysis Based on the National Health Insurance Service Database of Gangwon Province in South Korea

YEO JIN KIM
Chuncheon Sacred Heart Hospital

Sang Mi Kim
Ewha Womans University

Dae Hyun Jeong
Research Institute for Gangwon

Sang-Kyu Lee
Chuncheon Sacred Heart Hospital

Moo-Eob Ahn
Chuncheon Sacred Heart Hospital

Ohk-Hyun Ryu (✉️ ohryu30@gmail.com)
https://orcid.org/0000-0003-1118-6886

Research

Keywords: Metabolic syndrome, National Health Insurance Service, Dementia risk, Alzheimer’s disease, Vascular dementia

DOI: https://doi.org/10.21203/rs.3.rs-35451/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Metabolic syndrome is a cluster of conditions that occur together, increasing the risk of cardiovascular disease. However, the relationship between metabolic syndrome and dementia has remained controversial. Using nationwide population cohort data, we investigated the association between metabolic syndrome and dementia, according to the dementia type.

Methods

We analyzed data of 84,144 individuals in the aged group of more than 60 years, between January 1, 2009, to December 31, 2009, at Gangwon province by using the information of the (Korean) National Health Insurance Service. After eight years of gap, in 2017, we investigated the relationship between metabolic syndrome and dementia. We classified Dementia either as dementia of the Alzheimer type (AD) or vascular dementia (VD). AD and VD were defined according to criteria in the International Classification of Disease, Tenth Revision, Clinical Modification codes.

Results

Metabolic syndrome was associated with AD, while it was not associated with VD. All five components of metabolic syndrome were associated with AD, independently. However, among components of metabolic syndrome, only the high glucose level was associated with VD. Body Mass Index (BMI), fasting glucose and smoking were also associated with AD. A history of the previous stroke was associated with both AD and VD.

Conclusions

Metabolic syndrome was associated with AD, while it was not associated with VD. VD was associated only with several risk factors that could affect the vascular state rather than a metabolic syndrome. We suggested that the effect of metabolic syndrome on dementia would be different depending on the type of dementia.

Background

Metabolic syndrome is a cluster of components that indicates overnutrition and includes five components that are high blood pressure (BP), high blood glucose, high serum triglycerides (TG), low serum high-density lipoprotein cholesterol (HDL-C) and abdominal obesity. In particular, high blood pressure and blood glucose are the components of metabolic syndrome that are well known to be associated with dementia in late life. [1, 2] Metabolic syndrome has a greater potential to result in type 2 diabetes, lipid disorders, cardiovascular disease, stroke, and other circulatory disorders. Among them, cardiovascular and related diseases are the highest risk factor associated with metabolic syndrome, but whether cardiovascular diseases have any connection with dementia is not known. Previous studies between
metabolic syndrome and cognitive impairment were inconsistent. Some studies reported that metabolic syndrome was associated with increased risk of cognitive impairment, [3, 4] while other studies reported no association between the two, [5, 6] and even some reported that metabolic syndrome decelerated cognitive impairment.[7]

Of the numerous dementia etiologies, Alzheimer’s disease (AD) is the most common type of dementia, about 60% of the cases. Vascular dementia (VD) is the second most common type, accounting for about 20% of dementia. Cardiovascular risk factors could affect the development of both types, but the extent of their influences would depend on the type of dementia. VD had a leading cause in most cases, such as ischemia, haemorrhage, anoxia, or hypoxia, while causes of Alzheimer’s disease are not well understood. [8] Yet, previous studies that investigated the relationship between dementia and metabolic syndrome usually did not consider the type of dementia.

Gangwon province is located in the northeastern part of South Korea and is divided into two areas by the Mountains. It has an aged society with a relatively low population density in Korea. Although a large part of the population resides in the urban area, 11 out of 18 administrative areas have inadequate medical facilities because of the presence of mountains. That means this area is one of the most vulnerable areas of medical service in South Korea. The risk factors related to metabolic syndrome (cardiovascular and related diseases) are not well managed in this region therefore, characteristics of the disease might be different from other regions. Therefore, we analyzed the association of metabolic syndrome and its five components with the incident of dementia (a gap of eight years), according to the dementia type, in a population-based sample in Gangwon province, South Korea.

Methods

Data source and study population

The present study was conducted using data from the South Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC), which includes demographic information, medical use, disease information, lifestyle habits, and basic laboratory data.[9, 10] The NHIS registration is mandatory for all Koreans and the NHIS database represents health information for almost all populations in Korea.[11]

Patient data of Gangwon province in South Korea from January 1, 2009, to December 31, 2009, was included (n = 455,859). Of these patients, we selected only those aged more than 60 years (n = 105,786). Patients with dementia who was diagnosed before the index day were excluded (n = 21,642). In the end, 84,144 individuals were included in this study. We defined diagnoses using the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes.

Standard protocol approvals, registrations, and patient consents
This study was approved by the Institutional Review Board of Chuncheon Sacred Heart Hospital, and all methods were performed in accordance with the approved guidelines and regulations.

**Definition of dementia**

For defining dementia of the Alzheimer type (AD), the code of F00 or G30 was included but F01, F02, F03, F051, and G31 were excluded. For the definition of vascular dementia (VD), codes of F02 were included.

**Definition of Metabolic syndrome**

Individuals who met three or more of the five components were defined as having metabolic syndrome. Five components were abdominal obesity, high TG level, reduced HDL-C level, elevated BP, and elevated blood glucose.[12] Individuals having abdominal obesity were defined if waist circumference were over 90 cm in males and 80 cm in the female. Individuals having high TG level were defined if the serum TG level was over 150 mg/dL. Individuals having low HDL-C level were defined if serum HDL-C level was lower than 40 mg/dL in male and 50 mg/dL in the female. Individuals were defined as having elevated blood pressure if anti-hypertensive medications were prescribed or systolic blood pressure more than 130 mmHg and/or diastolic blood pressure more than 85 mmHg was recorded. Individuals having high blood glucose were defined if anti-diabetic drugs (insulins, sulphonylureas, metformin, meglitinides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and α-glucosidase inhibitors) were prescribed or fasting serum glucose level was over 100 mg/dL.

**Statistical analysis**

The baseline characteristics based on the data from the NHIS database are presented as mean values ± standard deviation (SD) for continuous variables and percentages for categorical variables. Differences between the metabolic syndrome group and non-metabolic syndrome group were confirmed using the Student t-test for continuous variables and chi-square tests for categorical variables. The relationship of metabolic syndrome and each component of metabolic syndrome for dementia was evaluated using multiple logistic regression analysis. We ran three regression models. In model 1, we performed multiple logistic regression analysis with metabolic syndrome or each of the components as determinant and AD or VD as outcome variables after controlling for age and gender. In model 2, we performed multiple logistic regression analysis with age, gender, smoking, alcohol, physical inactivity, and metabolic syndrome or five metabolic syndrome components (high TG, high BP, high blood glucose, abdominal obesity, and low HDL-C). In model 3, we performed multiple logistic regression analysis with age, gender, smoking, alcohol, physical inactivity, previous stroke, previous cardiac disease and metabolic syndrome or five metabolic syndrome components (high TG, high BP, high glucose, abdominal obesity, and low HDL-C). Again, the relationship of other vascular risk factors for dementia was evaluated using multiple logistic regression analysis. We also ran three regression models in this analysis. In model 1, we performed multiple logistic regression analysis with vascular risk factors as determinant and AD or VD as outcome variables after controlling for age and gender. In model 2, we performed multiple logistic regression analysis with age, gender, smoking, metabolic syndrome, BMI, systolic BP, diastolic BP, fasting glucose, total cholesterol. In model 3, we performed multiple logistic regression analysis with age, gender,
smoking, metabolic syndrome, BMI, systolic BP, diastolic BP, fasting glucose, total cholesterol, smoking, alcohol, physical inactivity, previous stroke, and previous cardiac disease. Disease risks were expressed as the odds ratio (OR) with 95% confidence interval (95% CI). We defined statistical significance as \( p < 0.05 \). Statistical analyses were conducted with SPSS version 25 software (SPSS Inc., Chicago, IL, USA).

**Data availability**

The original anonymized data used in this analysis was obtained from the NHIS of South Korea. The dataset from NHIS is not publicly available due to restricted access. However, any researcher requiring access to the data can obtain it directly through a license agreement, including the payment of appropriate license fees.

**Results**

**Demographics and baseline characteristics**

Detailed demographic and clinical characteristics of the participants are presented in Table 1. 40.2% of participants had metabolic syndrome. The mean age of the metabolic syndrome group was higher than the non-metabolic syndrome group. The metabolic syndrome group had a higher proportion of females than the non-metabolic syndrome group. The non-metabolic syndrome group had a higher level of physical inactivity, however, they also more engaged in smoking and alcohol intake. The mortality rate of both groups was similar.

After eight years, of the 33,828 patients with metabolic syndrome, 1,380 patients converted to AD and 335 patients converted to VD. Of the 50,316 patients with the non-metabolic syndrome, 176 patients converted to AD and 380 patients converted to VD.
Table 1
Demographics and baseline characteristics

|                                | Metabolic syndrome (n = 33,828) | Non-metabolic syndrome (n = 50,316) | p value |
|--------------------------------|---------------------------------|-------------------------------------|---------|
| Mean age                       | 67.42 ± 5.28                    | 66.79 ± 5.11                        | < 0.0001|
| Gender, female number<sup>a</sup> | 23,020 (68.1)                   | 25,088 (49.9)                       | < 0.0001|
| BMI                            | 25.88 ± 2.96                    | 23.68 ± 2.90                        | < 0.0001|
| Systolic BP                    | 136.61 ± 15.15                  | 126.54 ± 15.91                      | < 0.0001|
| Diastolic BP                   | 82.03 ± 10.12                   | 77.18 ± 9.97                        | < 0.0001|
| Fasting glucose                | 112.14 ± 31.27                  | 96.70 ± 20.45                       | 0.001   |
| Total cholesterol              | 200.80 ± 46.30                  | 194.55 ± 38.46                      | < 0.0001|
| Smoking, pack-year             | 1.33 ± 4.89                     | 2.16 ± 5.99                         | < 0.0001|
| Alcohol, cup/week              | 1.20 ± 2.94                     | 1.54 ± 3.20                         | < 0.0001|
| Previous stroke<sup>a</sup>    | 804(2.38)                       | 876(1.74)                           | < 0.0001|
| Previous cardiac disease<sup>a</sup> | 2,137(62.2)                  | 2,513(5.8)                          | < 0.0001|
| Previous HTN<sup>a</sup>       | 18,062(62.2)                    | 17,180(39.6)                        | < 0.0001|
| Previous DM<sup>a</sup>        | 6,969(24.1)                     | 4,102(9.5)                          | < 0.0001|
| Previous dyslipidemia<sup>a</sup> | 2,225(7.7)                    | 2,493(5.8)                          | < 0.0001|
| Physical inactivity<sup>a</sup> | 5,487(29.8)                     | 9,483(35.0)                         | < 0.0001|
| High TG<sup>a</sup>            | 21,746 (64.3)                   | 7,617 (15.1)                        | < 0.0001|
| High BP<sup>a</sup>            | 27,571 (81.5)                   | 22,848 (45.4)                       | < 0.0001|
Association between metabolic syndrome and AD

Table 2 shows the risk of AD according to the metabolic syndrome and component of the definition of metabolic syndrome.

Metabolic syndrome was associated with AD. (OR 11.476, 95% CI 9.026, 14.591, p < 0.0001). All five components of metabolic syndrome were also associated with AD independently. Patients with high TG had 1.872-fold odds of AD (OR 1.872, 95% CI 1.604, 2.185, p < 0.001). Patients with high BP had 1.847-fold odds of AD (OR 1.847, 95% CI 1.545, 2.209, p < 0.0001). Patients with high glucose levels had 1.767-fold odds of AD (OR 1.767, 95% CI 1.516, 2.058, p < 0.0001). Patients with obesity had 1.879-fold odds of Alzheimer’s disease (OR 1.879, 95% CI 1.567, 2.253, p < 0.0001). Patients with low HDL-C had 1.913-fold odds of AD (OR 1.913, 95% CI 1.633, 2.241, p < 0.0001).

| Metabolic syndrome (n = 33,828) | Non-metabolic syndrome (n = 50,316) | p value |
|-------------------------------|------------------------------------|--------|
| High glucose<sup>a</sup> | 22,422 (33.7) | 12,804 (74.6) | < 0.0001 |
| Abdominal obesity<sup>a</sup> | 26,806 (79.2) | 14,939 (29.7) | < 0.0001 |
| Low HDL-C<sup>a</sup> | 19,768 (58.4) | 8,377 (16.65) | < 0.0001 |

Data are mean ± SD unless otherwise indicated

<sup>a</sup> Number (%)

Abbreviations: BMI, body mass index; SD, standard deviation; BP, blood pressure; HTN, hypertension; DM, diabetes mellitus; TG, triglyceride; HDL-C, high density lipoprotein cholesterol
## Table 2
Metabolic syndrome and odds of the dementia in Alzheimer’s type

| Model       | MetS                      | OR (95% CI)       | p value | Hight TG                 | OR (95% CI)       | p value | High BP                   | OR (95% CI)       | p value | High glucose               | OR (95% CI)       | p value | Abdominal obesity          | OR (95% CI)       | p value | Low HDL-C                  | OR (95% CI)       | p value |
|-------------|---------------------------|-------------------|---------|---------------------------|-------------------|---------|---------------------------|-------------------|---------|---------------------------|-------------------|---------|---------------------------|-------------------|---------|---------------------------|-------------------|---------|
| Model 1     | 10.577                    | (9.018,12.406)    | <0.0001 | 2.264                     | (2.38,2.924)      | <0.0001 | 1.873                     | (1.665,2.108)    | <0.0001 | 2.308                     | (2.308,2.08)      | <0.0001 | 2.368                     | (2.099,2.671)     | <0.0001 | 2.332                     | (2.098,2.592)     | <0.0001 |
| Model 2     | 12.028                    | (9.579,15.102)    | <0.0001 | 2.003                     | (1.734,2.314)     | <0.0001 | 1.783                     | (1.514,2.100)    | <0.0001 | 1.838                     | (1.595,2.118)     | <0.0001 | 1.773                     | (1.501,2.093)     | <0.0001 | 1.952                     | (1.685,2.262)     | <0.0001 |
| Model 3     | 11.476                    | (9.026,14.591)    | <0.0001 | 1.872                     | (1.604,2.185)     | <0.0001 | 1.847                     | (1.545,2.209)    | <0.0001 | 1.767                     | (1.516,2.058)     | <0.0001 | 1.879                     | (1.567,2.253)     | <0.0001 | 1.913                     | (1.633,2.241)     | <0.0001 |

Model 1: separate models associated each exposure variable with Alzheimer’s disease with adjustment for age and gender

Model 2: single model including age, gender, smoking, alcohol, physical inactivity and metabolic syndrome or 5 metabolic syndrome components (high TG, high BP, high glucose, abdominal obesity, low HDL-C)

Model 3: single model including age, gender, smoking, alcohol, physical inactivity, previous stroke, previous cardiac disease and metabolic syndrome or 5 metabolic syndrome components (high TG, high BP, high glucose, abdominal obesity, low HDL-C)

Abbreviations: OR, odds ratio; CI, confidence interval; MetS, metabolic syndrome; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure

### Association between metabolic syndrome and VD

Table 3 shows the risk of VD according to the metabolic syndrome and component of the definition of metabolic syndrome.
Metabolic syndrome was not associated with VD (OR 1.173, 95% CI 0.940, 1.465, p = 0.158) Among five components of metabolic syndrome, high glucose was associated with VD independently. Patients with high glucose had 1.255-fold odds of VD (OR 1.255, 95% CI 1.008, 1.561, p = 0.042). High TG, high BP, obesity and low HDL-C were not associated with VD.

Table 3
Metabolic syndrome and odds of vascular dementia

|                  | Model 1 |          | Model 2 |          | Model 3 |          |
|------------------|---------|----------|---------|----------|---------|----------|
|                  | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value |
| MetS             | 1.084 (1.023, 1.148) | 0.006 | 1.171 (0.947, 1.448) | 0.144 | 1.173 (0.940, 1.465) | 0.158 |
| Hight TG         | 1.03 (0.883, 1.202) | 0.709 | 0.946 (0.756, 1.185) | 0.631 | 0.902 (0.712, 1.143) | 0.392 |
| High BP          | 1.068 (0.915, 1.246) | 0.404 | 1.310 (1.046, 1.642) | 0.019 | 1.246 (0.986, 1.575) | 0.066 |
| High glucose     | 1.295 (1.117, 1.501) | 0.001 | 1.286 (1.043, 1.585) | 0.019 | 1.255 (1.008, 1.561) | 0.042 |
| Abdominal obesity| 1.076 (0.919, 1.206) | 0.362 | 0.965 (0.770, 1.209) | 0.754 | 0.991 (0.782, 1.255) | 0.939 |
| Low HDL-C        | 1.028 (0.877, 1.204) | 0.736 | 0.972 (0.772, 1.223) | 0.806 | 0.967 (0.760, 1.230) | 0.785 |

Model 1: separate models associated each exposure variable with Alzheimer’s disease with adjustment for age and gender.

Model 2: single model including age, gender, smoking, alcohol, physical inactivity and metabolic syndrome or 5 metabolic syndrome components (high TG, high BP, high glucose, abdominal obesity, low HDL-C).

Model 3: single model including age, gender, smoking, alcohol, physical inactivity, previous stroke, previous cardiac disease and metabolic syndrome or 5 metabolic syndrome components (high TG, high BP, high glucose, abdominal obesity, low HDL-C).

Abbreviations: OR, odds ratio; CI, confidence interval; MetS, metabolic syndrome; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure
Association between other cardiovascular risk factors included continuous metabolic parameters and dementia

BMI, fasting glucose, smoking, and previous stroke history were associated with AD (Table 4). Patients with each 1-unit kg/m² higher BMI had 0.951-fold odds of AD. (OR 0.951, 95% CI 0.927, 0.975, p < 0.0001) Patients with each 1-unit mg/dL higher fasting glucose have 1.003-fold odds of AD. (OR 1.003, 95% CI 1.001, 1.005, p = 0.003) Patients with each 1-year higher pack/year smoking had 1.020-fold odds of AD (OR 1.020, 95% CI 1.003, 1.039, p = 0.024). Patients with having previous stroke history had 1.827-fold odds of AD. (OR = 1.827, 95% CI 1.263, 2.644, p = 0.001).

Fasting glucose and previous stroke history were associated with VD. Patients with each 1-unit mg/dL higher fasting glucose had 1.004-fold odds of VD (OR = 1.004, 95% CI 1.001, 1.008, p = 0.012). Patients with having previous stroke history had 2.775-fold odds of VD. (OR = 2.775, 95% CI 1.747, 4.406, p < 0.0001).
### Table 4
Odds of the dementia in Alzheimer's type or vascular dementia according to vascular risk factors

|                      | Alzheimer's disease | Vascular dementia |
|----------------------|---------------------|------------------|
|                      | Model 1             | Model 2          | Model 3          | Model 1 | Model 2 | Model 3          |
|                      | OR                  | OR               | OR               | OR      | OR      | OR               |
|                      | (95% CI)            | (95% CI)         | (95% CI)         | (95% CI)| (95% CI)| (95% CI)         |
|                      | p value             | p value          | p value          | p value | p value | p value          |
| BMI                  | 1.05 9 < 0.001      | 0.95 < 0.001     | 0.95 < 0.001     | 1.00    | 0.52    | 0.99 8 0.85     |
|                      | (1.0 42, 1.07 5)    | (0.9 41, 0.97 5) | (0.9 27, 0.975)  | (0.9 84,1.03 2) | (0.9 73, 1.02 3) | (0.9 52, 1.02 4) |
| Systolic BP          | 1.01 < 0.001       | 1.00 < 0.01      | 0.99 8 0.65      | 1.00    | 0.85    | 0.99 0.06 3     |
|                      | (1.0 11, 1.01 7)   | (0.9 95, 1.00 4) | (0.9 92, 1.00 5) | (0.9 96, 1.00 5) | (0.9 88, 1.00 0) | (0.9 90, 1.00 8) |
| Diastolic BP         | 1.01 < 0.001       | 0.99 6 0.21      | 1.00 1 0.91      | 1.00    | 0.07    | 1.00 0.01 4     |
|                      | (1.0 09, 1.01 8)   | (0.9 90, 1.00 2) | (0.9 91, 1.01 0) | (0.9 99, 1.01 4) | (1.0 02, 1.02 2) | (0.9 90, 1.01 9) |
| Fasting glucose      | 1.00 < 0.001       | 1.00 < 0.001     | 1.00 < 0.001     | 1.00    | < 0.00 2 | 1.00 < 0.001    |
|                      | (1.0 08, 1.01 1)   | (1.0 02, 1.00 5) | (1.0 01, 1.00 5) | (1.0 03, 1.00 7) | (1.0 02, 1.00 7) | (1.0 01, 1.00 8) |

Model 1: separate models associated each exposure variable with Alzheimer's disease with adjustment for age and gender

Model 2: single model including age, gender, metabolic syndrome, BMI, systolic BP, diastolic BP, Fasting glucose, total cholesterol

Model 3: single model including age, gender, metabolic syndrome, BMI, systolic BP, diastolic BP, Fasting glucose, total cholesterol, smoking, alcohol, physical inactivity, previous stroke and previous cardiac disease

Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; BP, blood pressure
|                      | Alzheimer's disease | Vascular dementia |
|----------------------|---------------------|-------------------|
| **Total cholesterol**| 1.00 0.00 1.00 0.21| 1.00 0.79 1.00 0.66 |
|                      | (1.00 2)           | (0.99 2)          |
| **Smoking**          | 1.00 0.28 1.02 1    | 1.02 0.02 0.82 0   |
|                      | (0.99 1)           | (0.99 1)          |
| **Alcohol**          | 0.99 0.69 1.02 1   | 0.97 0.30 0.97 0.15 |
|                      | (0.99 1)           | (0.99 1)          |
| **Physical inactivity** | 0.93 0.41 1.16 3  | 0.99 0.97 0.97 0.74 |
|                      | (0.94 1)           | (0.88 1)          |
| **Previous stroke**  | 2.24 < 2.77 <     | 1.82 0.00 2.46 <  |
|                      | 0.00 0.00 0.00 0   | 0.00 0.00 0.00 0   |
|                      | (1.75 2.87 4)      | (1.75 2.87 4)     |

Model 1: separate models associated each exposure variable with Alzheimer's disease with adjustment for age and gender

Model 2: single model including age, gender, metabolic syndrome, BMI, systolic BP, diastolic BP, Fasting glucose, total cholesterol

Model 3: single model including age, gender, metabolic syndrome, BMI, systolic BP, diastolic BP, Fasting glucose, total cholesterol, smoking, alcohol, physical inactivity, previous stroke and previous cardiac disease

Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; BP, blood pressure
### Discussion

We investigated how metabolic syndrome and related vascular risk factors are associated with the development of dementia after eight years. Metabolic syndrome was associated with AD, while it was not associated with VD. Rather than that, high fasting glucose and previous stroke history were found associated with VD. BMI, fasting glucose, smoking, and previous stroke were also found associated with AD.

The odds of metabolic syndrome were much greater than the sum of the odds of five components in AD. This might mean that the effect of metabolic syndrome, where risk factors coexist, on AD was greater than the sum of the effect of each component. Metabolic syndrome represented a chronic state of inflammation, hyperinsulinemia, dyslipidemia, dysglycemia, vascular injury and oxidative stress, which were linked to AD.[13] Amyloid beta (Aβ) deposition initiated an immune response, which was intended to clear the amyloid plaque.[14] However, this response also stimulated the cytokine cascade and reactive oxygen species (ROS), leading to neurodegeneration.[15] Furthermore, inflammatory cascade altered phosphorylation of tau protein along with the oxidative injury to the neurons. The immune response induced by amyloid, in addition to the chronic inflammatory state due to metabolic syndrome, exacerbated the AD pathogenic process, leading to a sufficient etiological factor to progress AD. [16, 17] Metabolic syndrome also induced oxidative stress and increased ROS production. The circulating lipid and glucose imbalance combined with ROS enhances lipoperoxidation, leading to the dysfunction of the antioxidant system. This causes vascular injury and blood-brain barrier (BBB) dysfunction, affecting amyloid and tau accumulation and chronic hypoperfusion, and leads to neuronal damage.[13]
Among components of metabolic syndrome, only high glucose level was found associated with both AD and VD, while others show association only with AD. Many previous studies have reported that diabetes mellitus not only affects cognitive decline but is also associated with a higher risk of cerebrovascular disease including high white matter hyperintensities volume, and cerebral infarcts. Impaired insulin signalling and glucose metabolism in the brain are factors that are related to AD pathogenesis. Insulin modulates Aβ protein precursor expression and processing.[18] Insulin not only regulates glucose and lipid metabolism in the brain but also regulates neural development and neuronal activities, associated with learning and memory.[19] Insulin receptors are expressed in the brain, particularly in memory registration-related areas, such as the cerebral cortex, hippocampus, hypothalamus, and amygdala.[20] Therefore, impairment of the insulin signalling leads to the pathologic processes of AD. In addition, we assumed that glucose metabolism would be more closely related to the mechanism that caused cognitive impairment after the vascular event. Although previous studies have shown that other vascular risk factors, such as hypertension [21], dyslipidemia [22], and abdominal obesity [23], also increase ischemic stroke. Our study showed that these factors were not associated with VD. Similar to our study, another study showed that high glucose was the most significant component that was associated with cognitive impairment.[24]

The previous stroke is also a factor that affects both AD and VD. The association between stroke and dementia has already been reported in several studies. Ischemic stroke was a risk factor for developing AD and VD.[25, 26] Stroke doubles the risk of dementia and approximately 20% of stroke patients go on to develop cognitive dysfunction within 3 years.[27] Ischemic stroke leads to pathophysiological processes that contribute to ischemic cell damage. Stimulation of the inflammatory process, free radical production, excitotoxicity, disruption of sodium and calcium influx, enzymatic changes, endothelin release, delayed coagulation, activation of platelets and leukocytes, and endothelial dysfunction are the pathophysiological reactions resulting from the onset of stroke.[28] Several studies reported a synergistic relationship between ischemic stroke and AD. Postmortem studies have shown that individuals with AD pathology with cerebral infarction had a markedly increased risk of dementia compared to those with AD pathology without infarcts.[29, 30] Stroke has been suggested as a contributing factor to AD pathological changes including selective brain atrophy and accumulation of abnormal protein such as Aβ.[31] A previous study also provided evidence that stroke leads to cognitive dysfunction more rapidly in patients with AD.[32] Besides, VD is the severest form of vascular cognitive impairment,[8] and it results from the subclinical vascular brain injury and stroke. Not only major stroke but also minor stroke and even transient ischemic attack are known to increase the risk of dementia.

As per our study, patients with higher BMI were less prone to AD. This result was consistent with so-called obesity paradox that high BMI in the elderly is associated with a lower risk of developing AD. Although obesity is linked to cardiovascular disease, the relationship between obesity and dementia is still not clear, especially in late-life. In previous studies, lower BMI was found associated with Aβ deposition, tau accumulation and cognitive decline.[33–35] It was also reported that high levels of leptin, a hormone synthesized by adipocytes, enhanced memory function.[36] In the present study, however, patients with obesity were diagnosed with more AD than patients without obesity. Therefore, the trend that patients
with higher BMI were less likely to have AD might be because patients with lower BMI had a higher risk of AD.

AD was also found associated with smoking. It is controversial whether smoking has any harmful effect on degenerative diseases. Previously some studies reported that smoking had a protective effect on degenerative diseases.[37–39] There are even researches which have shown that nicotine has a neuroprotective and anti-ageing effect.[40, 41] However, nowadays, smoking has been attributed as a risk factor for Alzheimer's disease.[42] Smoking increases oxidative stress and might have indirect effects on several vascular, inflammatory and degenerative processes.[43, 44] If smoking particles are inhaled, they stimulate ROS production and enters the brain via blood. Smoking-related cerebral oxidative stress is a potential mechanism to accelerate AD pathology and increase risk for AD.[45] Smoking also impairs nitric oxide synthesis in cerebral vascular endothelial cells leading to interference with cerebral blood flow and glucose metabolism in the brain. It induces cerebral hypoperfusion and promotes the synthesis of Aβ.[46] Smoking stimulates the release of proinflammatory cytokines and immune system-mediated products causing an increase in Aβ accumulation and tau phosphorylation, hallmarks of the AD pathology.[47]

Our study has some limitations. First, because our study used claim data, we classified the types of dementia, but the actual amyloid burden was unknown. However, in order to distinguish the pure dementia type, those with codes of both AD and VD were excluded. Second, since we only investigated the presence of dementia eight years later, there was no consideration what happened during the eight years and when dementia occurred during the eight years. Besides, there was no consideration for efforts to overcome metabolic syndrome. Some might have tried to treat metabolic syndrome, others might not, but the effect of improvement of metabolic syndrome was not known in our study. Third, it is also a cross-sectional study, there was no consideration for the duration of metabolic syndrome. The association with dementia might vary depending on how long components of metabolic syndrome have been existed, which were not known in our article. Therefore, further longitudinal study is required. Finally, as the cohort only included the specific region of Korea, further investigation in other region or population is needed to generalize these findings.

Despite these limitations, we investigated the effects of metabolic syndrome in different types of dementia and the association between vascular risk factors related to metabolic syndrome and dementia using population-based data. Therefore, we hope to provide new clinical insight into the association between metabolic syndrome and type of dementia with implications for considering different pathophysiology.

**Conclusions**

Metabolic syndrome was associated with AD, while it was not associated with VD. Therefore, the effect of metabolic syndrome on dementia would be different depending on the type of dementia.

**List Of Abbreviation**
AD : dementia of the Alzheimer type
VD : vascular dementia
BMI : Body Mass Index
BP : Blood Pressure
TG : triglycerides
HDL-C : high-density lipoprotein cholesterol
NHIS : (Korean) National Health Insurance Service
NHIS-NSC : National Health Insurance Service-National Sample Cohort
ICD-10-CM : International Classification of Disease, Tenth Revision, Clinical Modification
SD : standard deviation
OR : odds ratio
95% CI : 95% confidence interval
Aβ : amyloid beta
ROS : reactive oxygen species
BBB : blood-brain barrier

Declarations

Ethics approval and consent to participate
The study was approved by the institutional review board of Chuncheon Sacred Heart Hospital.

Consent for publication
Not applicable

Availability of data and material
The original anonymized data used in this analysis was obtained from NHIS of South Korea. The dataset from NHIS is not publicly available due to restricted access. However, any researcher requiring access to the data can obtain it directly through a license agreement, including the payment of appropriate license fees.
Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2017R1C1B2011637 & NRF-2019R1H1A1035599).

Authors’ contributions

Yeo Jin Kim interpreted the data and drafted the manuscript. Sang Mi Kim contributed to the study conceptualization and the discussion of results. Dae Hyun Jeong contributed to the study design and data analysis. Sang-Kyu Lee contributed to the data interpretation and the discussion of results. Moo-Eob Ahn contributed to the study design, data interpretation and the discussion of results. Ohk-Hyun Ryu contributed to the data interpretation, discussion of results and revising the manuscript.

Acknowledgements

Not applicable

References

1. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension. 2011;58(1):22–8. doi:10.1161/HYPERTENSIONAHA.110.163055.

2. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes. 2009;58(1):71–7. doi:10.2337/db08-0586.

3. Ho RC, Niti M, Yap KB, Kua EH, Ng TP. Metabolic syndrome and cognitive decline in chinese older adults: results from the singapore longitudinal ageing studies. Am J Geriatr Psychiatry. 2008;166:519–22. doi:10.1097/JGP.0b013e31816b7841.

4. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol. 2000;20 10:2255–60. doi:10.1161/01.atv.20.10.2255.

5. van den Berg E, Biessels GJ, de Craen AJ, Gussekloo J, Westendorp RG. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology. 2007;69 10:979–85. doi:10.1212/01.wnl.0000271381.30143.75.

6. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord. 2007;24 3:185–92. doi:10.1159/000105927.
7. Forti P, Pisacane N, Rietti E, Lucicesare A, Olivelli V, Mariani E, et al. Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc. 2010;58 3:487–92. doi:10.1111/j.1532-5415.2010.02731.x.

8. Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer's and vascular types. Biomed Res Int. 2014;2014:908915. doi:10.1155/2014/908915.

9. Choi JB, Lee EJ, Han KD, Hong SH, Ha US. Estimating the impact of body mass index on bladder cancer risk: Stratification by smoking status. Sci Rep. 2018;8 1:947; doi:10.1038/s41598-018-19531-7.

10. Song SO, Jung CH, Song YD, Park CY, Kwon HS, Cha BS, et al. Background and data configuration process of a nationwide population-based study using the korean national health insurance system. Diabetes Metab J. 2014;38 5:395–403. doi:10.4093/dmj.2014.38.5.395.

11. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol. 2017;236:226–31. doi:10.1016/j.ijcard.2017.02.039.

12. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120 16:1640–5; doi:10.1161/CIRCULATIONAHA.109.192644.

13. Luque-Contreras D, Carvajal K, Toral-Rios D, Franco-Bocanegra D, Campos-Pena V. Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer's disease? Oxid Med Cell Longev. 2014;2014:497802. doi:10.1155/2014/497802.

14. Calvillo M, Diaz A, Limon DI, Mayoral MA, Chanez-Cardenas ME, Zenteno E, et al. Amyloid-beta(25–35) induces a permanent phosphorylation of HSF-1, but a transitory and inflammation-independent overexpression of Hsp-70 in C6 astrocytoma cells. Neuropeptides. 2013;47 5:339–46. doi:10.1016/j.npep.2013.06.002.

15. Minter MR, Taylor JM, Crack PJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease. J Neurochem. 2016;136 3:457–74. doi:10.1111/jnc.13411.

16. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3 4:169–76. doi:10.1111/j.1474-9728.2004.00101.x.

17. Milionis HJ, Florentin M, Giannopoulos S. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? CNS Spectr. 2008;13 7:606–13. doi:10.1017/s1092852900016886.

18. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224–43. doi:10.1016/j.neurobiolaging.2008.04.002.
19. Gerozissis K. Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol. 2008;585 1:38–49. doi:10.1016/j.ejphar.2008.01.050.

20. Unger J, McNeill TH, Moxley RT, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 1989;31(1):143–57. doi:10.1016/0306-4522(89)90036-5.

21. Cipolla MJ, Liebeskind DS, Chan SL. The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation. J Cereb Blood Flow Metab. 2018;38 12:2129–49. doi:10.1177/0271678X18800589.

22. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285 21:2729–35. doi:10.1001/jama.285.21.2729.

23. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, et al. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34 7:1586–92. doi:10.1161/01.STR.0000075294.98582.2F.

24. Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, Seripa D, et al. Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis. 2010;21 1:57–63. doi:10.3233/JAD-2010-100015.

25. Chi NF, Chien LN, Ku HL, Hu CJ, Chiou HY. Alzheimer disease and risk of stroke: a population-based cohort study. Neurology. 2013;80 8:705–11. doi:10.1212/WNL.0b013e31828250af.

26. Gamaldo A, Moghekar A, Kilada S, Resnick SM, Zonderman AB, O'Brien R. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology. 2006;67 8:1363–9. doi:10.1212/01.wnl.0000240285.89067.3f.

27. Allan LM, Rowan EN, Firbank MJ, Thomas AJ, Parry SW, Polvikoski TM, et al. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain. 2011;134 Pt 12:3716–27. doi:10.1093/brain/awr273.

28. Vijayan M, Kumar S, Bhatti JS, Reddy PH. Molecular Links and Biomarkers of Stroke, Vascular Dementia, and Alzheimer's Disease. Prog Mol Biol Transl Sci. 2017;146:95–126. doi:10.1016/bs.pmbts.2016.12.014.

29. Snowdon DA. Brain Infarction and the Clinical Expression of Alzheimer Disease < subtitle > The Nun Study</subtitle>. JAMA: The Journal of the American Medical Association. 1997;277 10; doi: 10.1001/jama.1997.03540340047031.

30. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. The Lancet. 1999;354 9182:919–20. doi:10.1016/s0140-6736(99)02355-7.

31. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012;322(1–2):141–7. doi:10.1016/j.jns.2012.07.032.

32. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G. Relationship of vascular risk to the progression of Alzheimer disease. Neurology. 2006;67 8:1357–62.
33. Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, et al. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging. 2012;33 8:1599–608. doi:10.1016/j.neurobiolaging.2011.05.005.

34. Vidoni ED, Townley RA, Honea RA, Burns JM. Alzheimer's Disease Neuroimaging I. Alzheimer disease biomarkers are associated with body mass index. Neurology. 2011;77 21:1913–20. doi:10.1212/WNL.0b013e318238eec1.

35. Cronk BB, Johnson DK, Burns JM. Alzheimer's Disease Neuroimaging I. Body mass index and cognitive decline in mild cognitive impairment. Alzheimer Dis Assoc Disord. 2010;24 2:126–30. doi:10.1097/WAD.0b013e3181a6bf3f.

36. Harvey J, Solovyova N, Irving A. Leptin and its role in hippocampal synaptic plasticity. Prog Lipid Res. 2006;45 5:369–78. doi:10.1016/j.plipres.2006.03.001.

37. Tanner CM. Advances in environmental epidemiology. Mov Disord. 2010;25(Suppl 1):58–62. doi:10.1002/mds.22721.

38. Fahn S. Parkinson's disease: 10 years of progress, 1997–2007. Mov Disord. 2010;25(Suppl 1):2–14. doi:10.1002/mds.22796.

39. Nicoletti A, Pugliese P, Nicoletti G, Arabia G, Annesi G, Mari MD, et al. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. Mov Disord. 2010;25 14:2387–94. doi:10.1002/mds.23297.

40. Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci. 2008;13:492–504. doi:10.2741/2695.

41. Quik M, PerezXA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord. 2012;27 8:947–57. doi:10.1002/mds.25028.

42. Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Munoz Sanchez JL, Anstey KJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30 3:234–46. doi:10.1002/gps.4245.

43. Collins N, Sachs-Ericsson N, Preacher KJ, Sheffield KM, Markides K. Smoking increases risk for cognitive decline among community-dwelling older Mexican Americans. Am J Geriatr Psychiatry. 2009;17 11:934–42. doi:10.1097/JGP.0b013e3181b0f8df.

44. Rusanen M, Rovio S, Ngandu T, Nissinen A, Tuomilehto J, Soininen H, et al. Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer's disease: a population-based cardiovascular risk factors, aging and dementia study. Dement Geriatr Cogn Disord. 2010;30 3:277–84. doi:10.1159/000320484.

45. Calderon-Garciduenas L. Smoking and Cerebral Oxidative Stress and Air Pollution: A Dreadful Equation with Particulate Matter Involved and One More Powerful Reason Not to Smoke Anything! J Alzheimers Dis. 2016;54(1):109–12. doi:10.3233/JAD-160510.

46. Toda N, Okamura T. Cigarette smoking impairs nitric oxide-mediated cerebral blood flow increase: Implications for Alzheimer's disease. J Pharmacol Sci. 2016;131 4:223–32.
Figure 1

Flow chart of the study population